Author:
Röltgen Katharina,Cruz Israel,Ndung’u Joseph M.,Pluschke Gerd
Funder
Medicor Foundation
Swiss Tropical and Public Health Institute
Publisher
Springer International Publishing
Reference89 articles.
1. Junghanss T, Johnson RC, Pluschke G (2014) Mycobacterium ulcerans disease. In: Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ (eds) Manson’s tropical diseases, 23rd edn. Saunders, Edinburgh, pp 519–531
2. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46(10):3193–3196
3. Marsollier L, Prevot G, Honore N, Legras P, Manceau AL, Payan C et al (2003) Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. Int J Antimicrob Agents 22(6):562–566
4. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R et al (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49(8):3182–3186
5. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C et al (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51(11):4029–4035
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献